Phase I Clinical and Pharmacokinetic Study of CBP501 and Cisplatin Every 3 Weeks in Patients With Advanced Refractory Solid Tumors.

Trial Profile

Phase I Clinical and Pharmacokinetic Study of CBP501 and Cisplatin Every 3 Weeks in Patients With Advanced Refractory Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs CBP 501 (Primary) ; Cisplatin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Oct 2011 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 21 Oct 2011 Actual initiation date changed from Mar 2007 to Nov 2006 as reported by ClinicalTrials.gov.
    • 21 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top